Sorghum plants are provided which are capable of inducing haploidy by modifications in the genome related to a pollen-specific expressed patatin phospholipid producing haploid offspring and can be produced for hybrid breeding in short time by chromosome doubling inbred lines, that is, homozygous father and mother lines. In addition, methods are provided for producing transgenic and non-transgenic plant haploid inducers and improving the induction performance of plants.

Provided here are methods of using a mutated patatin-like phospholipase IIα (“pPLAIIα,” renamed here MATRILINEAL) to induce haploid induction in plants, cloning a pPLAIIα to induce haploid induction in plants, and genetically engineering a plant to contain a mutated pPLAIIα. Also provided are methods of applying topical and spray chemicals, lipids, and RNAi molecules to plants during pollination in order to induce haploid production. Further provided are methods of chemically treating plants during pollination to induce haploids while also reducing embryo abortion and increasing seed set.

Sorghum plants are provided which are capable of inducing haploidy by modifications in the genome related to a pollen-specific expressed patatin phospholipid producing haploid offspring and can be produced for hybrid breeding in short time by chromosome doubling inbred lines, that is, homozygous father and mother lines. In addition, methods are provided for producing transgenic and non-transgenic plant haploid inducers and improving the induction performance of plants.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

Provided here are methods of using a mutated patatin-like phospholipase IIα (“pPLAIIα,” renamed here MATRILINEAL) to induce haploid induction in plants, cloning a pPLAIIα to induce haploid induction in plants, and genetically engineering a plant to contain a mutated pPLAIIα. Also provided are methods of applying topical and spray chemicals, lipids, and RNAi molecules to plants during pollination in order to induce haploid production. Further provided are methods of chemically treating plants during pollination to induce haploids while also reducing embryo abortion and increasing seed set.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin/kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

The present invention relates to pharmaceutical compositions comprising a compound selected from the group consisting of: a) a polypeptide of SEQ ID NO:1, b) a functionally equivalent variant of the polypeptide according to a), c) a polynucleotide encoding a) or b), d) a vector comprising a polynucleotide according to c), e) a cell capable of secreting into the medium a polypeptide according to a) or b), and f) a nanoparticle comprising the polypeptide according to a) or b) and a pharmaceutically acceptable excipient. The invention also relates to the use of said compounds or pharmaceutical compositions for treatment and/or prevention of ischemia injury or ischemia/reperfusion injury in a subject.

Provided here are methods of using a mutated patatin-like phospholipase II (pPLAII, renamed here MATRILINEAL) to induce haploid induction in plants, cloning a pPLAII to induce haploid induction in plants, and genetically engineering a plant to contain a mutated pPLAII. Also provided are methods of applying topical and spray chemicals, lipids, and RNAi molecules to plants during pollination in order to induce haploid production. Further provided are methods of chemically treating plants during pollination to induce haploids while also reducing embryo abortion and increasing seed set.

Sorghum plants are provided which are capable of inducing haploidy by modifications in the genome related to a pollen-specific expressed patatin phospholipid producing haploid offspring and can be produced for hybrid breeding in short time by chromosome doubling inbred lines, that is, homozygous father and mother lines. In addition, methods are provided for producing transgenic and non-transgenic plant haploid inducers and improving the induction performance of plants.